Measuring Excretion of Gluten Immunogenic Peptides (GIPs): An Assay for Monitoring Gluten Exposure

GastroHep Pub Date : 2025-03-19 DOI:10.1155/ygh2/3859529
Sunari Kulasekera, Jaymini Pankhania, Carol Leppard, Jacquita Affandi, Sue Critchley, Glen Lichtenberger, Dewruwan Gammanpila, Christopher Reid, Geoffrey Forbes, Narelle Hadlow, Mina John
{"title":"Measuring Excretion of Gluten Immunogenic Peptides (GIPs): An Assay for Monitoring Gluten Exposure","authors":"Sunari Kulasekera,&nbsp;Jaymini Pankhania,&nbsp;Carol Leppard,&nbsp;Jacquita Affandi,&nbsp;Sue Critchley,&nbsp;Glen Lichtenberger,&nbsp;Dewruwan Gammanpila,&nbsp;Christopher Reid,&nbsp;Geoffrey Forbes,&nbsp;Narelle Hadlow,&nbsp;Mina John","doi":"10.1155/ygh2/3859529","DOIUrl":null,"url":null,"abstract":"<p>Individuals with coeliac disease are required to exclude all gluten from their diet to prevent small bowel inflammation and associated complications. Life-long adherence to a gluten-free diet is challenging because of the potential presence of gluten in common noncereal foods, cross-contamination, and potentially small amounts of gluten in cereal-based foods formally labelled as “gluten-free.” For people living with coeliac disease, current tests to monitor the efficacy of a gluten-free diet may not detect ongoing, low level, or intermittent unintentional gluten exposure. The iVYCHECK and iVYLISA assays by Biomedal detect gluten-derived peptides, which are resistant to digestion, known to be immunogenic and are excreted in urine and stool. The urine test is qualitative for recent short-term exposure while the faecal test is quantitative and reflects gluten exposure over a longer interval. Several studies have validated the performance of these assays in monitoring compliance to gluten-free diets. We sought to evaluate these assays in a community-based pathology service by comparing values obtained in individuals with no dietary restrictions compared with those following a gluten-free diet. We performed 124 assays in 21 subjects over 9 days. The quantitative faecal gluten immunogenic peptide assay was highly precise. Faecal gluten immunogenic peptide assays were moderately sensitive (66%) and highly specific (97%) while the urine assay had sensitivity of 100% and lesser specificity (48%). Both assays had very high negative predictive value (90%) for detection of clinically relevant levels of oral gluten, as verified by participant self-reported diet diary over a 9-day period. An episode of inadvertent gluten exposure in one individual on an otherwise gluten-free diet was associated with temporally high gluten immunogenic peptide levels in stool. The majority of participants regarded accidental gluten exposures as important to their health and rated monitoring for gluten contamination as their strongest reason for utilizing this assay. Our study was limited by use of self-report rather than independent tests of gluten intake or clinical disease markers; however, our findings do provide support for implementation of these assays to assist in monitoring efficacy of a gluten-free diet.</p>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"2025 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ygh2/3859529","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GastroHep","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ygh2/3859529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Individuals with coeliac disease are required to exclude all gluten from their diet to prevent small bowel inflammation and associated complications. Life-long adherence to a gluten-free diet is challenging because of the potential presence of gluten in common noncereal foods, cross-contamination, and potentially small amounts of gluten in cereal-based foods formally labelled as “gluten-free.” For people living with coeliac disease, current tests to monitor the efficacy of a gluten-free diet may not detect ongoing, low level, or intermittent unintentional gluten exposure. The iVYCHECK and iVYLISA assays by Biomedal detect gluten-derived peptides, which are resistant to digestion, known to be immunogenic and are excreted in urine and stool. The urine test is qualitative for recent short-term exposure while the faecal test is quantitative and reflects gluten exposure over a longer interval. Several studies have validated the performance of these assays in monitoring compliance to gluten-free diets. We sought to evaluate these assays in a community-based pathology service by comparing values obtained in individuals with no dietary restrictions compared with those following a gluten-free diet. We performed 124 assays in 21 subjects over 9 days. The quantitative faecal gluten immunogenic peptide assay was highly precise. Faecal gluten immunogenic peptide assays were moderately sensitive (66%) and highly specific (97%) while the urine assay had sensitivity of 100% and lesser specificity (48%). Both assays had very high negative predictive value (90%) for detection of clinically relevant levels of oral gluten, as verified by participant self-reported diet diary over a 9-day period. An episode of inadvertent gluten exposure in one individual on an otherwise gluten-free diet was associated with temporally high gluten immunogenic peptide levels in stool. The majority of participants regarded accidental gluten exposures as important to their health and rated monitoring for gluten contamination as their strongest reason for utilizing this assay. Our study was limited by use of self-report rather than independent tests of gluten intake or clinical disease markers; however, our findings do provide support for implementation of these assays to assist in monitoring efficacy of a gluten-free diet.

Abstract Image

测量谷蛋白免疫原肽(GIPs)的排泄:一种监测谷蛋白暴露的检测方法
患有乳糜泻的人需要从他们的饮食中排除所有麸质以防止小肠炎症和相关并发症。终身坚持无麸质饮食是具有挑战性的,因为普通非谷物食品中可能存在麸质,交叉污染,并且在正式标记为“无麸质”的谷物食品中可能含有少量麸质。对于患有乳糜泻的人来说,目前监测无麸质饮食效果的试验可能无法检测到持续的、低水平的或间歇性的无意的麸质暴露。生物医学公司的iVYCHECK和iVYLISA检测检测谷蛋白衍生肽,这些肽抵抗消化,已知具有免疫原性,并通过尿液和粪便排出。尿液测试对近期的短期接触是定性的,而粪便测试是定量的,反映了较长时间内的谷蛋白接触。几项研究证实了这些检测在监测无麸质饮食依从性方面的性能。我们试图在一个以社区为基础的病理服务中通过比较没有饮食限制的个体与无麸质饮食的个体获得的值来评估这些检测。我们在9天内对21名受试者进行了124次检测。定量测定粪谷蛋白免疫原性肽具有较高的准确性。粪便谷蛋白免疫原性肽检测具有中等敏感性(66%)和高度特异性(97%),而尿液检测的敏感性为100%,特异性较低(48%)。这两项检测在检测临床相关的口服谷蛋白水平方面都有很高的阴性预测值(90%),这一点得到了参与者在9天内自我报告的饮食日记的证实。一个人在无麸质饮食中不慎接触麸质与粪便中临时性高麸质免疫原性肽水平有关。大多数参与者认为意外接触谷蛋白对他们的健康很重要,并将监测谷蛋白污染作为他们使用该试验的最重要原因。我们的研究受限于使用自我报告而不是麸质摄入或临床疾病标志物的独立测试;然而,我们的研究结果确实为这些检测的实施提供了支持,以帮助监测无谷蛋白饮食的功效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信